Page 15 - CIBERER2016-ENG

EVOLUTION OF CIBERER PUBLICATIONS 2010-2016
900
800
700
600
500
400
300
200
100
0
TOTAL Q1 D1
Most relevant publications of the CIBERER in 2016 according to impact factor
2010
2011
2012
2013
2014
2015
2016
Publication
Impact factor
Latorre-Pellicer A., Moreno-Loshuertos R., Lechuga-Vieco A.V., Sanchez-Cabo F., Torroja C., Acin-Perez R. et al. Mitochondrial and nuclear DNA matching shapes metabolism and healthy ageing. Nature. 2016;535(7613):561-565.
38,891
Dunning A.M., Michailidou K., Kuchenbaecker K.B., Thompson D., French J.D., Beesley J. et al. Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics. 2016;48(4):374-38.
38,138
Zhou W., Machiela M.J., Freedman N.D., Rothman N., Malats N., Dagnall C. et al. Mosaic loss of chromosome Y is associated with common variation near TCL1A. Nature Genetics. 2016;48(5):563-568.
37,369
Kenna K.P., Van Doormaal P.T.C., Dekker A.M., Ticozzi N., Kenna B.J., Diekstra F.P. et al. NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. Nature Genetics. 2016;48(9):1037- 1042.
34,661
Van Rheenen W., Shatunov A., Dekker A.M., McLaughlin R.L., Diekstra F.P., Pulit S.L. et al. Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nature Genetics. 2016;48(9):1043-1048.
34,090
de la Torre R., de Sola S., Hernandez G., Farre M., Pujol J., Rodriguez J. et al. Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down’s syndrome (TESDAD): A double-blind, randomised, placebo-controlled, phase 2 trial. The Lancet Neurology. 2016;15(8):801-810.
34,090
ER
organisation 15